Last updated: September 2, 2026
Ethinyl estradiol/norgestrel is a mature combined oral contraceptive with limited branded exposure, extensive generic competition, and no meaningful patent-driven pricing power. The U.S. market is dominated by generic products equivalent to the former Lo/Ovral and Cryselle products. Revenue is likely stable in units but compressed in value because of low prices, pharmacy-benefit substitution, public-program purchasing, and competition from other combined oral contraceptives and progestin-only options.
The principal U.S. dosage is ethinyl estradiol 0.03 mg plus norgestrel 0.3 mg, supplied in 21-day and 28-day regimens. Norgestrel is a racemic mixture containing levonorgestrel, the pharmacologically active component. The product is prescription-only in its combined formulation, unlike norgestrel-only Opill, which received FDA approval for over-the-counter use in 2023. [1]
What is the market position of ethinyl estradiol/norgestrel?
Ethinyl estradiol/norgestrel occupies a mature, low-growth segment of the U.S. hormonal contraceptive market.
The product competes with:
- ethinyl estradiol/levonorgestrel tablets
- ethinyl estradiol/norethindrone products
- ethinyl estradiol/norgestimate products
- ethinyl estradiol/desogestrel products
- drospirenone/ethinyl estradiol products
- progestin-only pills
- long-acting reversible contraceptives
- depot medroxyprogesterone injections
- contraceptive implants and intrauterine systems
The product’s principal commercial advantages are low acquisition cost, established clinical familiarity, and broad generic availability. Its limitations are the absence of product differentiation, declining use of older oral contraceptive combinations in some prescribing settings, and competition from low-dose formulations with alternative progestins.
What products contain ethinyl estradiol and norgestrel?
| Product or product type |
Active ingredients |
U.S. status |
Commercial position |
| Cryselle-28 |
Ethinyl estradiol 0.03 mg/norgestrel 0.3 mg |
Prescription |
Branded or authorized generic reference product, depending on market availability |
| Lo/Ovral |
Ethinyl estradiol 0.03 mg/norgestrel 0.3 mg |
Historical branded product |
Originator brand with largely expired exclusivity |
| Generic equivalent tablets |
Ethinyl estradiol 0.03 mg/norgestrel 0.3 mg |
Prescription |
Main source of current U.S. volume |
| Opill |
Norgestrel 0.075 mg |
OTC |
Different formulation and indication; not a substitute for the combined product |
Cryselle-28 is listed in FDA labeling databases as an oral contraceptive containing ethinyl estradiol and norgestrel. [2] Lo/Ovral was historically associated with Wyeth, later part of Pfizer, and is no longer the primary commercial driver of the category.
How large is the ethinyl estradiol/norgestrel market?
No major manufacturer publicly reports standalone revenue for ethinyl estradiol/norgestrel. Public filings generally aggregate oral contraceptives within broader women’s-health, established-products, or generic-pharmaceutical categories. A defensible product-specific revenue estimate therefore cannot be derived from company filings alone.
The commercial profile is clear even without a reported product-level figure:
- The market is prescription-based.
- Generic substitution is extensive.
- Average selling prices are low relative to newer contraceptives.
- Volume is distributed across several manufacturers and pharmacy channels.
- Revenue is driven more by prescription count than by price increases.
The U.S. oral contraceptive market is materially larger than the ethinyl estradiol/norgestrel subsegment. IQVIA has historically classified products at molecule, formulation, and manufacturer levels, but public reports rarely disclose complete revenue for a single generic combination. [3]
What drives demand?
Demand is linked to contraceptive use, menstrual-cycle management, insurance coverage, public-sector procurement, and patient preference. The product can also be prescribed for dysmenorrhea and cycle regulation, although contraceptive use is the principal commercial indication.
Demand is relatively resilient because oral contraception is a recurring therapy. Prescription persistence is affected by tolerability, adherence, access, pregnancy planning, and switching to long-acting methods.
The principal demand pressures are:
- movement toward long-acting reversible contraception
- switching to progestin-only contraception
- safety-driven avoidance of estrogen in higher-risk patients
- preference for newer formulations or extended-cycle regimens
- increased availability of OTC contraception
- lower use among patients obtaining contraceptive implants or intrauterine systems
When did ethinyl estradiol/norgestrel lose exclusivity?
The meaningful patent and regulatory exclusivity periods for the original combined oral contraceptive products have expired. The product is now a mature generic medicine.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Original product patent protection |
Expired or commercially immaterial |
| Pediatric exclusivity |
Expired |
| Orphan exclusivity |
Not applicable |
| Generic competition |
Established |
| Biosimilar exclusivity |
Not applicable |
The relevant FDA-approved products have been on the market for decades. The commercial question is therefore not whether the originator can preserve exclusivity, but how many suppliers remain active and whether shortages or manufacturing withdrawals alter supply.
What is the Orange Book status of ethinyl estradiol/norgestrel?
The Orange Book identifies approved drug products and any listed patents or exclusivity associated with those products. For mature ethinyl estradiol/norgestrel tablets, current commercial risk is not based on an active composition-of-matter patent.
No biosimilar pathway applies because the product is a small-molecule oral tablet. Generic applicants use the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. [4]
Are there active Paragraph IV challenges?
Paragraph IV litigation is not a central current issue for ethinyl estradiol/norgestrel. The formulation is old, generic competition is established, and the principal reference-product patents have expired.
A new Paragraph IV dispute could arise only from a later-listed patent covering a specific formulation, delivery system, or method of use. Such a patent would need to present a commercially meaningful barrier against generic substitution. Standard immediate-release tablets have limited room for defensible patent differentiation.
What formulations are protected by patents?
The conventional ethinyl estradiol/norgestrel immediate-release tablet has little remaining patent value. Potentially protectable subject matter could include:
- extended-cycle dosing schedules
- modified-release tablets
- alternative packaging or regimen designs
- combination products with other active ingredients
- novel delivery systems
- manufacturing processes
- specific therapeutic uses
These categories have limited relevance to the standard generic product unless they create a separate FDA-approved product with its own market demand. Method-of-use patents generally have weaker commercial leverage in contraceptive products because physicians may prescribe generics for multiple clinically accepted uses and because pharmacies substitute based on product equivalence.
How strong is the patent estate for ethinyl estradiol/norgestrel?
The patent estate is weak from a commercial-exclusivity perspective.
| Patent factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Core tablet formulation protection |
Expired or commercially exhausted |
| Generic substitution barrier |
Low |
| Regulatory exclusivity |
Expired |
| Manufacturing know-how |
Moderate operational value, limited exclusionary value |
| Packaging or regimen patents |
Potentially narrow |
| Litigation leverage |
Low |
| Biosimilar protection |
Not applicable |
Manufacturing know-how can still matter. Hormonal tablets require controlled-content uniformity, impurity management, stability testing, and validated processes. Those factors can affect approval and supply reliability, but they do not normally create a durable monopoly once multiple manufacturers have approved products.
Which companies compete in the market?
The competitive field consists primarily of generic manufacturers and contract suppliers. Companies that have marketed or supplied oral contraceptive products in the broader U.S. market include:
- Glenmark Pharmaceuticals
- Amneal Pharmaceuticals
- Lupin
- Teva Pharmaceuticals
- Aurobindo Pharma
- Perrigo
- Dr. Reddy’s Laboratories
- Prasco Laboratories and other authorized-generic or contract-marketing entities
The active supplier list can change because generic manufacturers discontinue low-margin products, transfer applications, or maintain approval without continuous commercial distribution. FDA’s Drugs@FDA database and the Orange Book provide the relevant approval and therapeutic-equivalence records. [4,5]
How does ethinyl estradiol/norgestrel compare with ethinyl estradiol/levonorgestrel?
Ethinyl estradiol/levonorgestrel is generally more commercially prominent than ethinyl estradiol/norgestrel because levonorgestrel is widely used across several contraceptive products, including emergency contraception and intrauterine systems.
| Attribute |
EE/norgestrel |
EE/levonorgestrel |
| Product maturity |
Very mature |
Very mature |
| Generic competition |
High |
High |
| Clinical familiarity |
High |
High |
| Commercial differentiation |
Low |
Low to moderate |
| Broader contraceptive franchise |
Limited |
Larger |
| Patent leverage |
Minimal |
Minimal for standard tablets |
| Price outlook |
Low and pressured |
Low and pressured |
The pharmacologic relationship between norgestrel and levonorgestrel does not make the products interchangeable at the regulatory level. Each approved product must meet its own labeling and bioequivalence requirements.
What FDA regulatory issues affect the market?
The FDA has treated the standard combination as an established oral contraceptive product. Generic applicants must meet requirements for:
- active-ingredient identity and strength
- dissolution and content uniformity
- bioequivalence
- stability
- labeling
- manufacturing controls
- packaging and patient-information requirements
The combined product remains prescription-only because it contains estrogen and requires clinical screening for contraindications. The FDA’s approval of Opill for OTC use reflects a different risk-benefit assessment for norgestrel-only contraception. Opill does not eliminate the need for prescription combined oral contraceptives and does not directly expand the ethinyl estradiol/norgestrel market. [1]
What manufacturing and supply risks exist?
The principal risks are operational rather than intellectual property-related.
Manufacturing risks
- dependence on a limited number of active suppliers
- low margins that can prompt discontinuation
- API supply disruptions
- quality-system observations
- packaging-component shortages
- product-specific recalls
- wholesaler inventory concentration
- changes in Medicaid or public-program purchasing
Norgestrel and ethinyl estradiol are established APIs, so the market does not face the development risk associated with novel molecules. The risk is continuity of supply at acceptable cost.
A manufacturer with an efficient validated process can retain business through reliable fulfillment, even without patent protection. That advantage is commercial and temporary rather than legally exclusionary.
What revenue trajectory should investors expect?
The expected trajectory is mature and price-constrained:
- unit demand should remain relatively stable over time;
- nominal revenue is likely to decline or remain flat;
- generic price competition will limit gross-margin expansion;
- temporary shortages can produce short-term price increases;
- brand revenue is unlikely to recover without a differentiated reformulation;
- manufacturers with diversified women’s-health portfolios have greater resilience than single-product suppliers.
Revenue exposure is more significant at the category level than at the molecule level. A company may earn useful established-product revenue from the product, but ethinyl estradiol/norgestrel is unlikely to be a material growth driver for a large pharmaceutical company.
What could improve the financial outlook?
Potential upside would require a commercial change outside the standard generic tablet:
- an extended-cycle or modified-release product
- a consumer-facing brand with strong adherence positioning
- an approved OTC pathway for the combined product
- a differentiated packaging or digital-adherence model
- supply disruption affecting competitors
- a licensing arrangement transferring the product to a lower-cost manufacturer
- public-sector contracts with favorable volume economics
Each opportunity carries execution or regulatory risk. A new formulation would face competition from established generic and branded oral contraceptives.
What licensing deals affect ethinyl estradiol/norgestrel?
No major current licensing transaction is publicly associated with the standard ethinyl estradiol/norgestrel tablet as a growth asset. Historical brand ownership changed through broader pharmaceutical transactions, including the transfer of Wyeth assets to Pfizer. Generic products are often supplied through manufacturer, distributor, authorized-generic, and contract-marketing arrangements rather than high-value molecule licenses.
The absence of a major licensing market is consistent with the product’s status as an off-patent, low-price medicine.
What litigation and settlement risks exist?
Current litigation risk is limited compared with recently launched small-molecule medicines. The standard product is unlikely to generate meaningful patent-settlement economics because:
- core patents are expired;
- generic products are already marketed;
- product differentiation is limited;
- damages exposure is constrained by low unit pricing;
- no major exclusivity cliff remains.
Potential disputes could still involve manufacturing quality, product liability, labeling, supply agreements, or regulatory compliance. Those matters are separate from the historic patent estate.
What generic launch scenarios exist?
Base case
Generic manufacturers continue supplying the market. Prices remain low, volume stays recurring, and no single supplier gains durable control.
Consolidation case
One or more manufacturers withdraw because of low margins. Remaining suppliers obtain better utilization and may increase prices modestly, but substitute products remain available.
Shortage case
A quality event, API interruption, or manufacturing shutdown creates temporary shortages. Pharmacies and wholesalers shift demand to equivalent oral contraceptives, limiting the duration of any pricing benefit.
Reformulation case
A company launches a differentiated regimen or delivery system. The new product may obtain limited exclusivity, but it would compete against low-cost immediate-release tablets.
How does geographic coverage affect commercial value?
The U.S. market has the clearest regulatory and reimbursement structure, but the product is sold internationally under different brand and generic names. Regulatory status varies by country, and many jurisdictions have low-cost oral contraceptive procurement programs.
International value is constrained by:
- tender-based pricing
- local generic production
- national reimbursement controls
- currency exposure
- different contraceptive guidelines
- registration and pharmacovigilance requirements
The product can generate broad geographic volume, but geographic breadth does not imply high revenue per prescription.
Key Takeaways
- Ethinyl estradiol/norgestrel is a mature combined oral contraceptive with extensive generic competition.
- The standard 0.03 mg/0.3 mg tablet has no meaningful remaining composition-of-matter exclusivity.
- Orange Book and Paragraph IV issues are commercially limited for the established product.
- No biosimilar risk applies because this is a small-molecule tablet.
- Revenue is driven by recurring prescription volume, not pricing power.
- Product-level revenue is generally not disclosed by manufacturers.
- The main risks are supplier withdrawal, manufacturing disruption, quality events, and substitution by other contraceptive methods.
- Growth would require a differentiated formulation, new channel strategy, or a broader women’s-health portfolio.
- Opill’s OTC approval affects the contraceptive landscape but does not convert the combined ethinyl estradiol/norgestrel product to OTC status.
- The financial outlook is stable to declining in value, with limited prospects for a material rebound.
FAQs
Is ethinyl estradiol/norgestrel still sold in the United States?
Yes. The product is available primarily through generic and branded-generic channels, although specific manufacturers and pharmacy inventories can change.
Is Cryselle the same as ethinyl estradiol/norgestrel?
Cryselle-28 contains ethinyl estradiol 0.03 mg and norgestrel 0.3 mg. Generic equivalents must satisfy FDA requirements for pharmaceutical equivalence and bioequivalence.
Can Opill replace ethinyl estradiol/norgestrel?
No. Opill contains norgestrel alone and does not contain ethinyl estradiol. It is a progestin-only contraceptive with different labeling, contraindications, and clinical characteristics.
Does ethinyl estradiol/norgestrel have patent protection in Europe?
The original product and active ingredients are mature. Country-specific formulation, packaging, regulatory, and manufacturing rights may differ, but the core product is generally exposed to generic competition.
Is ethinyl estradiol/norgestrel an attractive licensing asset?
The standard product has limited licensing value as a standalone asset. Its value is more likely to arise from manufacturing efficiency, supply reliability, public-sector volume, or inclusion in a broader women’s-health portfolio.
References
- U.S. Food and Drug Administration. (2023). FDA approves first nonprescription daily oral contraceptive. https://www.fda.gov
- DailyMed. (n.d.). Cryselle-28: Norgestrel and ethinyl estradiol tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
- IQVIA. (2024). The global use of medicines and 2024 outlook. IQVIA Institute for Human Data Science.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
